Cara Therapeutics to Present at the American Academy of Physical Medicine and Rehabilitation Annual Assembly
September 28, 2015 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., Sept. 28, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics to Present Data at the 8th World Congress on Itch
September 22, 2015 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., Sept. 22, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative Pain
September 09, 2015 08:00 ET
|
Cara Therapeutics
First Pivotal Trial Will Evaluate I.V. CR845, Dosed Pre- and Postoperatively, in Patients Undergoing Abdominal Surgery
Top-line data expected in 1H'2016
SHELTON, Conn., Sept. 9, 2015 (GLOBE...
Cara Therapeutics to Webcast Presentation at 22nd Annual NewsMakers in the Biotech Industry Conference
September 03, 2015 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics to Sponsor Symposium and Present Posters at PAINWeek
September 01, 2015 08:00 ET
|
Cara Therapeutics
Pain Experts to Discuss Developments in Kappa Opioid Receptor Agonists and the Future of Pain Management
Company to Present Positive Data From Phase 2 Acute Pain and Human Abuse Liability...
Cara Therapeutics Initiates Phase 2 Trial of Oral CR845 in Osteoarthritis
August 17, 2015 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., Aug. 17, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics Reports Second Quarter 2015 Financial Results
August 10, 2015 16:01 ET
|
Cara Therapeutics
Reported statistically-significant positive top-line results from Phase 2 trial for I.V. CR845 in uremic pruritus
Completed successful public offering of common stock, raising net proceeds of...
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
August 04, 2015 16:01 ET
|
Cara Therapeutics
SHELTON, Conn., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics to Announce Second Quarter 2015 Financial Results on August 10, 2015
August 03, 2015 16:30 ET
|
Cara Therapeutics
SHELTON, Conn., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to selectively...
Cara Therapeutics Announces Pricing of Its Public Offering of Common Stock
July 29, 2015 19:10 ET
|
Cara Therapeutics
SHELTON, Conn., July 29, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...